Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Offidani, M
Right arrow Articles by Leoni, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Offidani, M
Right arrow Articles by Leoni, P
Haematologica, Vol 91, Issue 1, 133-136
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial, Phase II

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study

M Offidani, L Corvatta, M Marconi, G Visani, F Alesiani, M Brunori, P Galieni, M Catarini, M Burattini, R Centurioni, S Rupoli, AR Scortechini, L Giuliodori, M Candela, D Capelli, M Montanari, A Olivieri, MN Piersantelli, and P Leoni

Clinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Universita Politecnica delle Marche. m.offidani@ao-umbertoprimo.marche.it

The aim of this prospective, multicenter, phase II study was to investigate the combination of pegylated liposomal doxorubicin (Caelyx) 40 mg/m2 on day 1 every 28 days, dexamethasone 40 mg p.o. on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma. Twenty-six percent of patients achieved a complete response, 6% a near complete response, 6% a very good partial response, 38% a partial response, 16% a minor response and 8% progressed, for an overall response rate of 92%. The median event-free survival was 17 months and the median overall survival was not reached. Grade 3 non-hematologic toxicity occurred in 12% of patients, thromboembolic disease in 12% and severe infection in 16%. The combination of pegylated liposomal doxorubicin, dexamethasone an thalidomide is safe and very effective in advanced multiple myeloma.


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al.
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
Ann. Onc., June 1, 2008; 19(6): 1160 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al.
Thalidomide for treatment of multiple myeloma: 10 years later
Blood, April 15, 2008; 111(8): 3968 - 3977.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman
The Risk of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
P. Richardson, C. Mitsiades, R. Schlossman, I. Ghobrial, T. Hideshima, D. Chauhan, N. Munshi, and K. Anderson
The Treatment of Relapsed and Refractory Multiple Myeloma
Hematology, January 1, 2007; 2007(1): 317 - 323.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.